BBIOBridgeBio Pharma, Inc.
Pharmaceutical Preparations
- Revenue
- $502M
- 126% YoY
- Operating margin
- -104.2%
- 61% YoY
- EBITDA
- −$518M
- 12% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $1.1B net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired26% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-11% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $70M | $78M | $9M | $222M | $502M | 126% |
| Operating income | −$577M | −$512M | −$607M | −$593M | −$523M | 12% |
| Operating cash flow | −$498M | −$419M | −$528M | −$521M | −$446M | 14% |
| Capex | $13M | $5M | $1M | $933K | $1M | 18% |
| Stock-based comp | $100M | $92M | $109M | $96M | $133M | 39% |
| Buybacks | $200M | $0 | $0 | $0 | $48M |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $3M · 5
- Net
- −$3M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $15M | $75M | 108 | 125 |
| FY2024 | $16M | −$3M | 39 | 93 |
| FY2023 | $12M | $70M | 57 | 94 |
| FY2022 | $7M | −$11M | 11 | 90 |
| FY2021 | $26M | −$133M | 23 | 100 |